Alligator Bioscience gives update on mitazalimab
In parallel with ongoing partnering activities, Alligator is exploring alternative opportunities for phase 3 development of mitazalimab in first line metastatic pancreatic cancer.
As part of these efforts, Alligator has signed a letter-of-intent with the French non-for-profit clinical cancer research organization Unicancer. Consequently, the parties are collaborating to establish the feasibility of, and prepare for, a global investigator sponsored Phase 3 study.
No development decisions have been taken at this time, and any such activities remain at an exploratory stage, the company states.
Updated: April 15, 2026, 09:04 am
Published: April 13, 2026
